In particular, BiTEs are designed to recruit and activate cytotoxic T cells by simultaneously binding to a tumor antigen, such as EGFR or MET, and the CD3 receptor on T cells, facilitating targeted activation and tumor cell lysis [193]. The gene discussed is EGFR; the disease is neoplasm.